(Q35580143)

9 August 2017

title

Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease (English)

1 reference

9 August 2017

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

30 March 2024

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

30 March 2024

1

Bertram Pitt

1 reference

9 August 2017

Sanjay Rajagopalan

3

1 reference

9 August 2017

Charles T. Stier

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14608520

30 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14608520

30 March 2024

publication date

1 September 2003

1 reference

full work available at URL

9 August 2017

https://doi.org/10.3317/jraas.2003.025

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14608520

http://journals.sagepub.com/doi/pdf/10.3317/jraas.2003.025

30 March 2024

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

Journal of the Renin-Angiotensin-Aldosterone System

30 March 2024

published in

1 reference

9 August 2017

volume

4

1 reference

9 August 2017

issue

3

1 reference

9 August 2017

page(s)

164-168

1 reference

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Aldosterone in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Factors controlling steroid biosynthesis in the zona glomerulosa of the adrenal

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Endothelin-1 and the adrenal gland

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Effects of spironolactone on systolic blood pressure in experimental diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Workshop: mechanisms and cardiovascular damage in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Mineralocorticoid receptor antagonism in experimental atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Inhibition of adrenal cell aldosterone synthesis by endogenous nitric oxide release

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Effects of high sodium intake on cardiovascular aldosterone synthesis in stroke-prone spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Oxidative stress and renal dysfunction in salt-sensitive hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Effect of salt loading on nitric oxide synthase expression in normotensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Adverse cardiac effects of salt with fludrocortisone in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Fibrosis and hypertensive heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Angiotensin, fibrinolysis, and vascular homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocard

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.025

Journal of the American College of Cardiology

21 January 2018

5

35

212A

Cody RJ

2000

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

American Journal of Physiology

30 March 2024

8

269

E657

Young M.

1995

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

Chronic administration of aldosterone depresses baroreceptor reflex function in the dog

30 March 2024

10

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

Aldosterone blunts the baroreflex response in man

30 March 2024

11

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo

30 March 2024

13

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure

30 March 2024

14

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors

30 March 2024

15

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor

30 March 2024

16

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

Vascular aldosterone in genetically hypertensive rats

30 March 2024

18

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation

30 March 2024

19

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

Regulation of aldosterone secretion

30 March 2024

26

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

Hypoxia causes down-regulation of 11 beta-hydroxysteroid dehydrogenase type 2 by induction of Egr-1.

30 March 2024

36

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats

30 March 2024

38

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland

30 March 2024

45

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats

30 March 2024

51

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

Remodeling of the rat right and left ventricles in experimental hypertension

30 March 2024

53

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

Nitric oxide and cardiac autonomic control in humans

30 March 2024

60

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves

30 March 2024

61

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis

30 March 2024

62

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.025

30 March 2024

Identifiers

1 reference

9 August 2017

1 reference